01—Abstract
Summary
Summary of the 8-K filed October 31, 2024. Cited figures are marked; the original filing is the authoritative source.
Merck's third-quarter 2024 results (8-K filed October 31, 2024) showed total sales of $16.7 billiona, up 4% reported and 7% excluding foreign exchange, led by KEYTRUDA, which grew 17% to $7.4 billion (21% ex-FX).
Growth was partially offset by declines in GARDASIL/GARDASIL 9 (down 11%, largely on lower demand in China), JANUVIA/JANUMET (down 42%) and LAGEVRIO (down 40%). Animal Health sales rose 6% to $1.5 billionb, and WINREVAIR, launched in the U.S. in the second quarter, reached $149 million in sales. Earnings were depressed by business development charges.
GAAP EPS was $1.24c versus $1.86 a year earlier, and non-GAAP EPS was $1.57 versus $2.13, with both figures including a net $0.79 per-share charge tied to the EyeBio and Curon acquisitions and a Daiichi Sankyo payment. Non-GAAP gross margin improved to 80.5% from 77.0%, reflecting favorable product mix and lower royalty rates on KEYTRUDA and GARDASIL. Full-year 2024 guidance was mixed.
Sales guidance was narrowed to $63.6 to $64.1 billiond from $63.4 to $64.4 billion, and the non-GAAP EPS range was lowered to $7.72 to $7.77 from $7.94 to $8.04, reflecting a net $0.24 per-share negative impact from the Curon and Daiichi Sankyo transactions. Management said the outlook assumes no additional significant business development transactions.
02—Key points
Key Highlights
- Q3 2024 sales rose 4% to $16.7 billion (7% excluding FX), driven by KEYTRUDA, which grew 17% to $7.4 billion.
- GAAP EPS fell 33% to $1.24 and non-GAAP EPS fell 26% to $1.57, mainly due to a $0.79 per-share net charge from the EyeBio, Curon and Daiichi Sankyo transactions.
- Non-GAAP gross margin expanded to 80.5% from 77.0%, reflecting favorable product mix and lower royalty rates.
- GARDASIL/GARDASIL 9 sales declined 11% to $2.3 billion on weaker demand in China, though sales grew double digits outside China in almost every major region.
- Full-year 2024 sales guidance was narrowed to $63.6 to $64.1 billion, with the midpoint slightly below the prior range midpoint.
- Full-year 2024 non-GAAP EPS guidance was lowered to $7.72 to $7.77 from $7.94 to $8.04, reflecting a $0.24 per-share net charge from the Curon acquisition and the Daiichi Sankyo payment.
- WINREVAIR generated $149 million in Q3 sales in its first full quarter of U.S. launch momentum and gained EU approval, with more than 3,700 patients prescribed as of September 2024.
03—Questions
Frequently Asked Questions
Why did Merck's EPS decline so sharply in the third quarter of 2024?
The decline was driven mainly by business development charges rather than weaker operations. Merck recorded a net charge of $0.79 per share for the EyeBio acquisition and related milestone, the CN201 (MK-1045) acquisition from Curon, and a partially offsetting $170 million payment received from Daiichi Sankyo. Q3 2023 had no significant business development charges. GAAP EPS was $1.24 versus $1.86, and non-GAAP EPS was $1.57 versus $2.13.
How did KEYTRUDA perform, and why does it matter?
KEYTRUDA was the main growth driver, with Q3 sales up 17% to $7.4 billion (21% excluding FX). Growth came from earlier-stage indications, including triple-negative breast cancer, renal cell carcinoma and non-small cell lung cancer, along with continued strong demand in metastatic settings. Because KEYTRUDA is Merck's largest product, its trajectory largely determines the company's near-term revenue growth.
Did Merck change its 2024 financial guidance?
Yes, mixed. Sales guidance was narrowed to $63.6 to $64.1 billion from $63.4 to $64.4 billion, which is a tighter range. Non-GAAP EPS guidance was lowered to $7.72 to $7.77 from $7.94 to $8.04, mainly because of a $0.24 per-share net charge from the Curon acquisition and the Daiichi Sankyo payment. The outlook excludes any additional significant business development transactions.
What are the main risks to Merck's growth outlook?
The filing points to several risks: GARDASIL/GARDASIL 9 demand weakness in China, which fell sharply in the quarter; JANUVIA/JANUMET declines from U.S. pricing and generic competition; LAGEVRIO's 40% sales decline; and foreign exchange, with the Argentine peso devaluation costing roughly 2 percentage points of sales growth. Merck also noted general risks around patents, competition, regulation and pipeline execution.
04—Continue